exv10w1



 








Exhibit 10.1




COST REIMBURSEMENT



SUBCONTRACT AGREEMENT



BETWEEN



CASE WESTERN RESERVE UNIVERSITY



AND



CYBERKINETICS NEUROTECHNOLOGY SYSTEMS, INC.



UNDER CONTRACT HHSN275200503403C



THIS AGREEMENT, by and between Case Western Reserve University, hereinafter referred to as “CWRU”
and Cyberkinetics Neurotechnology Systems, Inc. whose principal place of business is 100 Foxborough
Boulevard, Suite 240, Foxborough, Massachusetts 02045 hereinafter referred to as “SUBCONTRACTOR”,
is for the purpose as hereinafter set forth.



WHEREAS, CWRU is the recipient of the following award (hereinafter referred to as “PRIME AWARD” and
attached hereto as Exhibit A ) which is incorporated herein. All terms and conditions and
applicable clauses of the PRIME AWARD are carried forth and shall apply to this AGREEMENT:




	 	 	 
	Award Number:

	 	HHSN275200503403C
	Project Sponsor:

	 	NIH — NICHD
	Project Title:

	 	Controller Development for Upper Limb Movement
	CWRU Principal Investigator:

	 	Robert F. Kirsch
	SUBCONTRACTOR Principal Investigator:

	 	John Donoghue






And WHEREAS, said PRIME AWARD involves an approved collaborative effort between CWRU and
SUBCONTRACTOR where SUBCONTRACTOR has agreed to use its personnel, facilities, and reasonable
efforts in the performance of the work, THEREFORE, the parties mutually agree as follows:



ARTICLE I. STATEMENT OF WORK




SUBCONTRACTOR shall provide the necessary personnel, facilities, data and materials to perform the
services specified in the attached statement of work, marked Exhibit B, which by this reference is
incorporated herein.



ARTICLE II. SCHEDULE FOR DELIVERABLE ITEMS OR REPORTS OR BOTH




In connection with and as part of the work to be performed, SUBCONTRACTOR shall submit reports as
specified in the Statement of Work attached hereto and as otherwise required by CASE under the
terms of the PRIME AWARD.



ARTICLE III. PERIOD OF PERFORMANCE




Performance of this AGREEMENT shall begin September 2, 2005 and continue through * * * as the
initial period of performance. A final completion date is anticipated by * * *. Subsequent periods
of performance shall be extended, by amendment of this AGREEMENT, which shall be in writing and
signed by all parties to this AGREEMENT.



ARTICLE IV. ESTIMATED COST AND PAYMENT



The
estimated cost of this Agreement is USD * * *  for the initial period of
the contract. Total funds currently available for payment and
allotted to this agreement are  * * *. CWRU shall not, in the absence
of a modification



 




*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



1









 





hereto, be obligated to reimburse the Subcontractor for costs which
are in excess of the currently allotted amount specified in this article. Subcontractor shall
expend funds in strict accordance with the budget contained in Exhibit C, which is attached hereto
and made a part hereof.



It is estimated that the amount currently allotted will cover performance of the Agreement through
* * *.



CWRU may allot additional funds to the Agreement without the concurrence of the Subcontractor.



Negotiated increments for future periods are:



	 	 	 
	PERIOD	 	AMOUNT
	* * *

	 	* * *
	* * *

	 	* * *
	* * *

	 	* * *
	* * *

	 	* * *






The total amount shall not exceed * * * without the prior written approval of CWRU.



The funding for this Agreement is subject to and contingent upon the continuing availability of
Federal funds for the purpose hereof.



SUBCONTRACTOR shall submit itemized invoices to CWRU not more frequently than monthly. The final
invoice must be submitted no later than 60 days after the completion date. Said invoices must
represent actual expenses paid and be certified by an appropriate institutional official.
Subcontractor shall use NIH Invoice/Financing Request Form, NIH Form (RC-1), contained in
Attachment 1 to the Prime Award (Exhibit A) and shall reference the CWRU number RES501126.



Submit an original and one copy to:



	 	 	 
	Robert F. Kirsch

	 	Tel: (216) 368-3158
	Case Western Reserve University

	 	Fax: (216) 368-4969
	Department of Biomedical Engineering

	 	E-mail address: rfk3@case.edu
	10900 Euclid Avenue
	 	 
	Cleveland, OH 44106-7207
	 	 






For the purpose of determining the amount payable to SUBCONTRACTOR under this AGREEMENT, the
allowability of costs shall be determined in accordance with the Federal Acquisition Regulation
(FAR) and the Health and Human Services Acquisition Regulations (HHSAR), and the terms of this
AGREEMENT.



ARTICLE V. FEDERAL AGENCY AUDIT




Acceptance of AGREEMENT obligates the parties to comply with audit provisions applicable to Federal
agency grantees. SUBCONTRACTOR agrees to permit independent auditors to have access to any other
records and financial statements as necessary for CWRU to comply with regulations applicable to the
AGREEMENT and make available to CWRU such information and records as CWRU may reasonably request to
facilitate CWRU compliance with said requirements.



ARTICLE VI. PROJECT DIRECTOR (CWRU)



The project director representing CWRU for the purpose of technical direction of the contracts
performance shall be Dr. Robert F. Kirsch. Any changes to the scope of work by the Subcontractor
must be approved in writing by Dr. Kirsch.



ARTICLE VII. PROJECT DIRECTOR (SUBCONTRACTOR)






 




*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



2









 






The project director representing SUBCONTRACTOR for the purpose of technical direction in
accordance with Article I, shall be:



John Donoghue, PhD.

Cyberkinetics Neurotechnology Systems, Inc.,

100 Foxborough Blvd., Suite 240

Foxborough, MA 02035

Phone: (508) 549-9981, ext. 102

Fax: (508) 549-9985




jdonoghue@cyberkineticsinc.com




A change in the designated project director shall require the prior written approval of CWRU.



ARTICLE VIII. SPECIAL PROVISIONS.




	 	1.	 	The performance of SUBCONTRACTOR under this AGREEMENT shall conform to the requirements
of the PRIME AWARD, the Federal Acquisition Regulations and the Health and Human Services
Acquisition Regulations, as applicable. If the SUBCONTRACTOR is a non-US Institution, U.S.
Government regulations included herein apply only as specified by the Federal Acquisition
Regulations and the Health and Human Services Acquisition Regulations, as applicable.
	 
	 	2.	 	SUBCONTRACTOR agrees to maintain books, records, and documents and other evidence
pertaining to all costs and expenses incurred and revenues acquired under this AGREEMENT to
the extent and in such detail as will properly reflect all costs and expenses of whatever
nature for which reimbursement is claimed. The books of account and other records which are
applicable to this AGREEMENT shall at all times be available for inspection, review, and
audit by CWRU to determine proper application and use of all funds paid to or for the
account of benefit of SUBCONTRACTOR.
	 
	 	3.	 	This AGREEMENT may not be assigned in whole or in part without the prior written
consent of CWRU .
	 
	 	4.	 	SUBCONTRACTOR assumes sole responsibility for reimbursement to CWRU of a sum of money
equivalent to the amount of any expenditures disallowed should DHHS rule through audit
exception or other
appropriate means that expenditures from funds allocated to SUBCONTRACTOR were not made in
compliance with the regulations of DHHS or the provisions of the AGREEMENT.
	 
	 	5.	 	CWRU, through its authorized representative, has the right, upon reasonable advance
notice, at all reasonable times, to inspect or otherwise evaluate the work performed or
being performed by SUBCONTRACTOR.





ARTICLE IX. HEALTH AND SAFETY




The SUBCONTRACTOR is responsible for meeting Federal, State, and local health and safety standards
and for establishing and implementing necessary measures to minimize their employees’ risk of
injury or illness in activities related to NIH contracts.



ARTICLE X. HUMAN SUBJECTS



The internal practices of each Participating Institution shall apply to its portion of the project;
these practices shall be in compliance with applicable Federal Regulations as found in the PRIME
AWARD, Section H – Special Contract Requirements, Articles H.1, H.2, and H.15, and in HHSAR
352.270-8 “Protection of Human Subjects,” that can be found in full text at
http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&%3C?SID%3E&rgn=div8&view=text&node=48:4
 .0.1.8.25.1.1.21&idno=48



The question of whether human subjects involved in the work undertaken by one
Participating Institution will be




 




*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



3









 





placed at risk by the work planned at the other Participating
Institution shall be a matter for decision by both institution’s Institutional Review Board (IRB);
these Boards shall communicate directly when either judges it appropriate, with a record of the
final disposition provided to both. IRB review and approvals shall be completed before any
procedures can be initiated on human subjects.



By execution of this AGREEMENT, SUBCONTRACTOR also assures CWRU that all locations at which
portions of the project that involve the use of human subjects are carried out and have on file a
current Federal Wide Assurance through the Office of Human Research Protection (OHRP).
Cyberkinetics number is * * *.



ARTICLE XI. VERTEBRATE ANIMALS




Should warm-blooded animals be used in this project, SUBCONTRACTOR will comply with the applicable
portions of the Animal Welfare Act (P.L. 99-158) and will follow the guidelines prescribed in the
Public Health Services Policy on Humane Care and Use of Laboratory Animals.



ARTICLE XII. RECOMBINANT DNA




For all research involving recombinant DNA techniques, the SUBCONTRACTOR agrees to meet the
requirements of the NIH Guidelines for Research Involving Recombinant DNA Molecules (the
Guidelines) (59 FR 34496, July 5, 1994 or latest revision).



ARTICLE XIII. PATENTS AND INVENTIONS




Patent and invention rights will be in accordance with Government regulations as set forth in 37
CFR 401, as noted in the Federal Acquisition Regulations and the Health and Human Services
Acquisition Regulations.




	 	1.	 	Invention means any invention or discovery which is or may be patentable or otherwise
protectable under Title 35 of the United States Code, or any novel variety of plant which
is or may be protected under the Plant Variety Protection Act (7 U.S.C. 2321 et seq.).
	 
	 	2.	 	Subject Invention means any Invention of CWRU or SUBCONTRACTOR conceived or first
actually reduced to practice in the performance of work under this contract, provided
that in the case of a variety of plant, the date of determination [as defined in section
41 (d) of the Plant Variety Protection Act, 7 U.S.C. 2401 (d) ] must also occur during
the period of contract performance.
	 
	 	3.	 	Each party may retain the entire right, title, and interest throughout the world to
each Subject Invention subject to the provisions of 37 CFR 401.14 and 35 U.S.C. 203.
With respect to any Subject Invention in which that party retains title, the Federal
Government shall have a nonexclusive, nontransferable, irrevocable, paid-up license to
practice or have practiced for or on behalf of the United States the Subject Invention
throughout the world.
	 
	 	4.	 	If any Subject Invention is developed jointly by employees or agents of both parties,
both parties shall jointly own (without any duty to account to the other for profits) all
right, title and interest (including patents, copyrights, mask work rights, trade
secrets, and other intellectual property rights) therein. Both parties will engage in
good faith efforts to mutually agree on whether and how to pursue patent, copyright or
mask work protection of the invention in the U.S. and elsewhere. There shall be
appointed a technical advisory board consisting of an equal number of representatives
from each party. Upon the generation of
a Subject Invention that a party believes to be jointly developed with the other party,
such party shall so advise the other party, and the technical advisory board shall
determine which party made the greater contribution to the Subject Invention in question.
If the technical advisory board cannot reach a decision upon the matter, it shall be
referred to arbitration under Article XV hereof. The party that is determined to have
made the greater contribution shall take the lead in obtaining intellectual property
protection regarding the Subject Invention in question (the “Lead Party”). In the event
that it is determined that both parties made equal contributions, then for the first such
situation of a determination of equal
contributions the Lead Party shall be determined by
a toss of the coin. For subsequent determination of equal







 




*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



4









 






	 	 	 	contributions the parties shall
alternate in taking the role as Lead Party. The Lead Party shall keep the other party
fully advised of the steps being taken in regard to obtaining intellectual property
protection. If the other party disagrees with an action(s) of the Lead Party the matter
shall be submitted to arbitration, under Article XV hereof upon a request made by the
objecting party, if the request is made within thirty days of the objecting party learning
of the action in question. If either party fails to pay one-half of the expenses of
obtaining particular intellectual property protection within sixty days of being presented
with the bill for such, that party shall thereby forfeit all rights to practice under that
intellectual property protection in the country where such protection is being obtained.
	 
	 	5.	 	Each party shall have licensing and commercialization rights and options as will be
defined in an agreement which shall be made an addendum hereto which is currently being
negotiated in good faith by the parties. A copy of said agreement will be provided to
the National Institute of Child Health and Human Development (NICHD).
	 
	 	6.	 	If and when a Subject Invention is created that may be amenable to patenting and/or
licensing, the CWRU Principal Investigator will disclose the Subject Invention to the CWRU
Technology Transfer Office (“TTO”) and/or the SUBCONTRACTOR Principal Investigator will
disclose the Subject Invention to the SUBCONTRACTOR’s intellectual property office, each in
accordance with their respective policies and practices, thereby creating a “Disclosure.”
Each party will promptly notify the other party in writing of receipt of any Disclosure,
normally within four weeks (“Notification”). In no event shall the Notification be
delivered to a party with an insufficient period of time for that party to meet its
reporting requirements to the Federal Government.
	 
	 	7.	 	Regarding its sole Subject Inventions, each party may, at its discretion and consistent
with the requirements of 37 CFR 401.14(c)(3), file an application for, and take steps to
obtain and maintain the validity of a patent(s) related to a Disclosure, in the United
States and/or any other country, and/or may take any other action (such as Copyright
registration) to obtain other protection in any country.
	 
	 	8.	 	Each party agrees that it will advise their respective employees that it is necessary
to hold in confidence all technical information and know-how received from the other party
(the “Confidential Information”) in connection with this Agreement and that it will not
disclose any Confidential Information of the other party and will allow the review of any
proposed patent applications or other protective measures containing joint Subject
Inventions to ensure that no Confidential Information is included. The obligation of
nondisclosure will not apply to the extent Confidential Information (i) was known to the
receiving party at the time it was disclosed, other than by previous disclosure by the
disclosing party, as evidenced by the receiving party’s written records at the time of
disclosure; (ii) is at the time of disclosure or later becomes publicly known under
circumstances involving no breach of this Agreement; (iii) is lawfully and in good faith
made available to the receiving party by a third party who did not derive it, directly or
indirectly, from the disclosing party; or (iv) is independently developed by a receiving
party without the use of the disclosing party’s Confidential Information.





ARTICLE XIV. INTANGIBLE PROPERTY RIGHTS AND PUBLICATION




The Subcontractor agrees to acknowledge the support of CWRU and the NIH awarding unit whenever
activities funded in whole or in part by this subcontract are published in any news media. Any
survey, questionnaire or publication arising from and supported by this subcontract will include a
positive statement clearly setting forth that the contents are in no way the responsibility of the
NIH awarding unit. Rights in intangible property will be in accordance with Government regulations
as set forth 45 CFR 74.36, and the terms of the PRIME AWARD
regarding the NIH rights in copyrightable material and the disposition of royalties and other
income earned from a Copyrighted work as noted in the Federal Acquisition Regulations and the
Health and Human Services Acquisition Regulations.



The rights in data developed jointly will be jointly owned by the parties, and if developed solely
by one party, will be owned solely by that party; the data, itself, is the property of the U.S.
Government. Each party grants to the other party a non-exclusive, royalty-free license to use the
data developed solely by each other provided that each party uses such data only for its own
internal research and educational purposes. The parties agree to negotiate in good



 






*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



5









 





faith
in the
event that either requests a license for commercial purposes. In the event that there is any
discrepancy between this Article XIV and the Federal Acquisition Regulations (FAR) Clause No.
52.227-17 entitled “Rights in Data – Special Works,” the FAR Clause shall apply.



Publication of data and/or discoveries arising from the performance of the research investigation
described in the Statement of Work will be governed by scientific custom with respect to authorship
and may be subject to restriction based upon the need to protect confidential information and/or to
seek patent protection. CWRU and SUBCONTRACTOR acknowledge and agree that, to the extent a
proposed disclosure or publication includes data and/or discoveries from clinical trials conducted
at third party sites, such data and/or discoveries may not be disclosed or published prior to the
publication of the results of such clinical trials or confirmation with the third party site(s).
To this end, the Project Director, (CWRU) and the Project Director (SUBCONTRACTOR), in
collaboration with the NICHD Project Officer, will jointly review all proposed publications prior
to submission. Subject to publication of the results of the clinical trials described above, any
delay will not exceed * * * for the purpose of filing patents.



ARTICLE XV DISPUTE RESOLUTION




Any controversy or dispute arising under this Agreement (including, but not limited to, the
validity, scope and enforceability of this arbitration clause) shall be referred to and finally
settled by arbitration in the City of Cleveland, Ohio, under the auspices of, and conducted in
accordance with, the rules of the American Arbitration Association. All arbitration proceedings
shall be before a board of three (3) arbitrators, for each of which each party shall select one (1)
arbitrator and the selected arbitrators shall select the third arbitrator. The costs of the third
arbitrator shall be divided equally between the parties, and each party shall pay the costs of the
arbitrator selected by it. Any award of the arbitrators shall be final and conclusive on the
parties to this Agreement, and judgment upon such award may be entered in any court having
jurisdiction thereof.



Either party may seek injunctive relief for enforcement of this Dispute Resolution Article.



SUBCONTRACTOR hereby irrevocably and unconditionally:




	 	1.	 	Agrees that any legal action, suit or proceeding contemplated by this Section entitled
“Dispute Resolution” hereof (collectively, “Related Litigation”) may be brought in any
state or federal court of competent jurisdiction sitting in Cuyahoga County, Ohio, submits
to the jurisdiction of such courts, and to the fullest extent permitted by law agrees that
it will not bring any Related Litigation in any other forum (but nothing herein shall
affect the right of CWRU to bring any action, suit or proceeding in any other forum);
	 
	 	2.	 	Waives any objection which it may have at any time to the laying of venue of any
Related Litigation brought in any such court located in Cuyahoga County, Ohio, waives any
claim that any such Related Litigation has been brought in an inconvenient forum, and
waives any right to object, with respect to any Related Litigation brought in any such
court, that such court does not have jurisdiction over Licensee; and
	 
	 	3.	 	Consents and agrees to service of any summons, complaint or other legal process in any
Related Litigation by registered or certified mail, postage prepaid, to Licensee at the
address for notices described in the Section entitled “Notices” hereof, and consents and
agrees that such service shall constitute in every respect valid and effective service (but
nothing herein shall affect the validity or effectiveness of process served in any other
manner permitted by law).





ARTICLE XVI TERMINATION




In the event of termination of the PRIME AWARD, this AGREEMENT shall be automatically terminated as
of the termination date of the PRIME AWARD. SUBCONTRACTOR will be reimbursed for any noncancelable
obligations properly incurred up to the date of notice of termination.



ARTICLE XVII. INCORPORATION OF APPLICABLE PROVISIONS OF THE PRIME AWARD



 






*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



6









 





All applicable provisions of the PRIME AWARD between CWRU and NIH, shall be binding upon
SUBCONTRACTOR as noted in the Federal Acquisition Regulations and the Health and Human Services
Acquisition Regulations and as listed in EXHIBIT A1.



ARTICLE XVIII. PUBLICITY




No publicity matter having or containing any reference to the other party to this Agreement, or in
which the name of the other party is mentioned, shall be made use of until written approval has
first been obtained by the party making use of the other party’s name.



ARTICLE XIX. CIVIL RIGHTS, AGE DISCRIMINATION AND EQUAL EMPLOYMENT OPPORTUNITY




SUBCONTRACTOR will comply with TITLE VI of the Civil Rights Act of 1964, Executive Order 11246, and
the Age Discrimination Act of 1975. SUBCONTRACTOR assures CWRU that it has valid Assurances of
Compliance with the DHHS for compliance with the Civil Rights Act of 1964 (Form HHS 441) and
section 504 of the Rehabilitation Act of 1973, as amended (Form HHS 641).



ARTICLE XX. SCIENTIFIC MISCONDUCT




Subcontractor hereby certifies that it has established procedures for dealing with and reporting
possible misconduct in science as set forth in 42 CFR Part 50, Subpart A. The term “Scientific
Misconduct” means, the fabrication, falsification, plagiarism, or other practices that seriously
deviate from those that are commonly accepted within the scientific community for proposing,
conducting, or reporting research.



ARTICLE XXI. CONFLICT OF INTEREST




In accordance with DHHS rule entitled, “Responsibility of Applicants for Promoting Objectivity in
Research for which PHS Funding is Sought” (42 CFR Part 50, Subpart F), SUBCONTRACTOR certifies that
it has established Conflict of Interest Policy that complies with all requirements, rules,
procedures, and principles of 42 CFR Part 50, Subpart F, incorporated herein by reference. If
Subcontractor does not have a Conflict of Interest Policy, it agrees to abide by and comply with
all rules, regulations, and procedures of CWRU’s Conflict of Interest Policy
(http://ora.ra.cwru.edu/main_research_compliance_page.htm). Upon written request by CWRU,
Subcontractor also agrees to furnish a copy of its Conflict of Interest Policy to CWRU within 30
days of receipt of request.



ARTICLE XXII. DEBARMENT AND SUSPENSION




SUBCONTRACTOR certifies to the best of its knowledge and belief that it is not presently debarred,
suspended, or proposed for debarment or declared ineligible for the awards of consortia, by any
Federal Agency, in accordance with the OMB Guidelines (53 FR19161-19211).



ARTICLE XXIII. CERTIFICATION OF NON-DELINQUENCY ON FEDERAL DEBT




SUBCONTRACTOR certifies that it is in compliance with the Non-Delinquency on Federal Debt criteria,
in accordance with OMB circular A-129.



ARTICLE XXIV. CERTIFICATION OF DRUG-FREE WORKPLACE




SUBCONTRACTOR certifies that it has implemented an appropriate policy in accordance with the
Drug-Free Workplace Act of 1988, 45 CFR Part 76, Subpart F.



ARTICLE XXV. CERTIFICATION REGARDING LOBBYING




SUBCONTRACTOR certifies to the best of its knowledge and belief that no Federal appropriated funds
have been paid or will be paid, by or on the behalf of the SUBCONTRACTOR, to any person for
influencing or attempting to influence a Federal
officer or Federal employee of any agency in
connection with the awarding of any federal award




 





*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



7









 





(Section 1352, Title 31, 4.5 Code).



ARTICLE XXVI. CLEAN AIR AND WATER




(Applicable only if the award exceeds $100,000 or a facility to be used has been the subject of a
conviction under the Clean Air Act or the Federal Water Pollution Control Act, and is listed by
EPA, or if the award is not otherwise exempt.)



The recipient agrees as follows:



1) To comply with applicable standards, orders or regulations issued pursuant to the Clean Air Act,
as amended (42 USC 7401, et seq.) and of the Federal Water Pollution Control Act (33 USC 1251 et
seq.), 2) That no portion of the work under this award will be performed in a facility listed on
the Environmental Protection Agency (EPA) List of Violating Facilities on the date that this award
was effective unless and until the EPA eliminates the name of the facility or facilities from such
listings, 3) To use its best efforts to comply with clean air standards and clean water standards
at the facility in which the award is being performed.



ARTICLE XXVII. LIABILITY




Each party shall be responsible for its negligent acts or omissions and the negligent acts or
omissions of its employees, officers, and directors.



ARTICLE XXVIII. INDEPENDENT CONTRACTOR




SUBCONTRACTOR is and will be acting as an independent contractor in the performance of this work.
Neither the SUBCONTRACTOR nor its employees or agents shall be deemed employees of CWRU while
performing under this agreement.



ARTICLE XXIX. REPRESENTATION




Representatives of the Parties to this Consortium are as follows:



A. For CWRU





	I.  	 	Research Issues — Dr. Robert F. Kirsch — Tel:
(216) 368-3158 — Email: rfk3@case.edu
	 
	II. 	 	Fiscal Issues —  Paul Frey, Grants Accounting —
Tel. (216) 368-5930 — Email:
pbf@case.edu
	 
	III.	 	Contract Issues — Tricia Mehosky, Sponsored Projects
Administration — (216) 368-5307 —
Email:pam17@case.edu





B. For SUBCONTRACTOR





	I.  	 	Research Issues — Dr. John Donoghue, Chief
Scientific Officer — Tel: (508) 549-9981, ext.
102 — email: jdonoghue@cyberkineticsinc.com 
	 
	II. 	 	Fiscal Issues — David Keene, Controller — Tel:
(508) 549-9981, ext. 113 — email:
dkeene@cyberkineticsinc.com
	 
	III.	 	Contract Issues — J. Christopher Flaherty, Executive Vice President Intellectual Property
and Technology — Tel: (508) 549-9981, ext. 106 — email: 
jcflaherty@cyberkineticsinc.com; and Jessica Duda, Director of
Corporate Development —
Tel: (508) 549-9981, ext. 112 — email: jduda@cyberkineticsinc.com





ARTICLE XXX. ENTIRE AGREEMENT




This AGREEMENT constitutes the entire agreement between CWRU and SUBCONTRACTOR with respect to the
subject matter hereof. No waiver, modification or amendment of any of the terms or conditions
hereof shall be effective unless set forth in writing and duly signed by CWRU and SUBCONTRACTOR.



In WITNESS THEREOF, the parties have executed this agreement by their duly authorized officers on
the date first




 



*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



8









 





herein set out:



	 	 	 	 	 	 	 	 	 	 	 
	CASE WESTERN RESERVE UNIVERSITY	 	CYBERKINETICS NEUROTECHNOLOGY SYSTEMS, INC.
	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Eric M. Cottington 	 	 	 	By:	 	/s/ Kimi Iguchi 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Signature
	 	 	 	 	 	Signature	 	 
	Date:

	 	      3/31/06 	 	 	 	Date:	 	      3/31/06 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 
	Eric M. Cottington, Ph.D.

Associate Vice President for Research

Office of Research Administration

10900 Euclid Avenue

Cleveland, Ohio 44106-7015 
	 	 	 	 	VP Finance 	 	 







 





*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.




9









 








EXHIBIT
A — Prime Award




Intentionally omitted.




 





*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



 









 





EXHIBIT
A1 — Clauses Incorporated by Reference




This contract incorporates the following clauses by reference, with the same force and effect,
as if they were given in full text. The full text of the clauses may be access electronically at
http://www.arnet.gov/far.



	 	 	 	 	 	 	 
	Reg	 	Clause	 	Date	 	Clause Title
	FAR

	 	52.202-1
	 	Jul-04
	 	Definitions (Over $100,000)
	FAR

	 	52.203-3
	 	Apr-84
	 	Gratuities (Over $100,000)
	FAR

	 	52.203-5
	 	Apr-84
	 	Covenant Against Contingent Fees (Over $100,000)
	FAR

	 	52.203-6
	 	Jul-95
	 	Restrictions on Subcontractor Sales to the Government (Over $100,000)
	FAR

	 	52.203-7
	 	Jul-95
	 	Anti-Kickback Procedures (Over $100,000)
	FAR

	 	52.203-8
	 	Jan-97
	 	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over $100,000)
	FAR

	 	52.203-10
	 	Jan-97
	 	Price or Fee Adjustment for Illegal or Improper Activity (Over $100,000)
	FAR

	 	52.203-12
	 	Sep-05
	 	Limitation on Payments to Influence Certain Federal Transactions (Over $100,000)
	FAR

	 	52.204-4
	 	Aug-00
	 	Printed or Copied Double-Sided on Recycled Paper (Over $100,000)
	FAR

	 	52.204-7
	 	Oct-03
	 	Central Contractor Registration
	FAR

	 	52.209-6
	 	Jan-05
	 	Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or
Proposed for Debarment (Over $25,000)
	FAR

	 	52.215-2
	 	Jun-99
	 	Audit and Records – Negotiation (Over $100,000)
	FAR

	 	52.215-8
	 	Oct-97
	 	Order of Precedence – Uniform Contract Format
	FAR

	 	52.215-10
	 	Oct-97
	 	Price Reduction for Defective Cost or Pricing Data
	FAR

	 	52.215-12
	 	Oct-97
	 	Subcontractor Cost or Pricing Data (Over $500,000)
	FAR

	 	52.215-14
	 	Oct-97
	 	Integrity of Unit Prices (Over $100,000)
	FAR

	 	52.215-15
	 	Oct-04
	 	Pension Adjustments and Asset Reversions
	FAR

	 	52.215-18
	 	Jul-05
	 	Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions
	FAR

	 	52.215-19
	 	Oct-97
	 	Notification of Ownership Changes
	FAR

	 	52.215-21
	 	Oct-97
	 	Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data – Modifications
	FAR

	 	52.216-7
	 	Dec-02
	 	Allowable Cost and Payment
	FAR

	 	52.216-11
	 	Apr-84
	 	Cost Contract – No Fee
	FAR

	 	52.219-8
	 	May-04
	 	Utilization of Small Business Concerns (Over $100,000)







							
	FAR

	 	52.219-9
	 	Jul-05
	 	Small Business Subcontracting Plan (Over $500,000)
	FAR

	 	52.219-16
	 	Jan-99
	 	Liquidated Damages – Subcontracting Plan (Over $500,000)
	FAR

	 	52.222-2
	 	Jul-90
	 	Payment for Overtime Premium (Over $100,000) (Note: The dollar amount in paragraph (a) of this clause is
$0 unless otherwise specified in the contract.)
	FAR

	 	52.222-3
	 	Jun-03
	 	Convict Labor
	FAR

	 	52.222-21
	 	Feb-99
	 	Prohibition of Segregated Facilities
	FAR

	 	52.222-26
	 	Apr-02
	 	Equal Opportunity
	FAR

	 	52.222-35
	 	Dec-01
	 	Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans
	FAR

	 	52.222-36
	 	Jun-98
	 	Affirmative Action for Workers with Disabilities
	FAR

	 	52.222-37
	 	Dec-01
	 	Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans
	FAR

	 	52.223-6
	 	May-01
	 	Drug-Free Workplace
	FAR

	 	52.223-14
	 	Aug-03
	 	Toxic Chemical Release Reporting (Over $100,000)
	FAR

	 	52.225-1
	 	Jun-03
	 	Buy American Act – Supplies
	FAR

	 	52.225-13
	 	Feb-06
	 	Restrictions on Certain Foreign Purchases
	FAR

	 	52.227-1
	 	Jul-95
	 	Authorization and Consent, Alternate I (Apr 1984)
	FAR

	 	52.227-2
	 	Aug-96
	 	Notice and Assistance Regarding Patent and Copyright Infringement (Over $100,000)
	FAR

	 	52.227-11
	 	Jun-97
	 	Patent Rights – Retention by the Contractor (Short Form) (Note: In accordance with FAR 27.303(a)(2),
paragraph (f) is modified to include the requirements in FAR 27.303(a)(2)(i) through (iv). The frequency
of reporting in (i) is annual.
	FAR

	 	52.227-17
	 	Jun-87
	 	Rights in Data – Special Works
	FAR

	 	52.232-9
	 	Apr-84
	 	Limitation on Withholding of Payments
	FAR

	 	52.232-17
	 	Jun-96
	 	Interest (Over $100,000)
	FAR

	 	52.232-20
	 	Apr-84
	 	Limitation of Cost
	FAR

	 	52.232-23
	 	Jan-86
	 	Assignment of Claims
	FAR

	 	52.232-25
	 	Oct-03
	 	Prompt Payment, Alternate I (Feb 2002)
	FAR

	 	52.233-1
	 	Jul-02
	 	Disputes
	FAR

	 	52.233-3
	 	Aug-96
	 	Protest After Award, Alternate I (Jun 1985)
	FAR

	 	52.233-4
	 	Oct-04
	 	Applicable Law for Breach of Contract Claim
	FAR

	 	52.242-1
	 	Apr-84
	 	Notice of Intent to Disallow Costs
	FAR

	 	52.242-3
	 	May-01
	 	Penalties for Unallowable Costs (Over $500,000)
	FAR

	 	52.242-4
	 	Jan-97
	 	Certification of Final Indirect Costs







							
	FAR

	 	52.242-13
	 	Jul-95
	 	Bankruptcy (Over $100,000)
	FAR

	 	52.243-2
	 	Aug-87
	 	Changes – Cost Reimbursement, Alternate V (Apr 1984)
	FAR

	 	52.244-2
	 	Aug-98
	 	Subcontracts, Alternate I (January 2006)
	FAR

	 	52.244-5
	 	Dec-96
	 	Competition in Subcontracting (Over $100,000)
	FAR

	 	52.244-6
	 	Feb-06
	 	Subcontracts for Commercial Items
	FAR

	 	52.245-5
	 	May-04
	 	Government Property (Cost-Reimbursement, Time and Material, or Labor-Hour Contract)
	FAR

	 	52.246-23
	 	Feb-97
	 	Limitation of Liability (Over $100,000)
	FAR

	 	52.249-6
	 	Sep-96
	 	Termination (Cost-Reimbursement)
	FAR

	 	52.249-14
	 	Apr-84
	 	Excusable Delays
	FAR

	 	52.253-1
	 	Jan-91
	 	Computer Generated Forms
	HHSAR

	 	352.202-1
	 	Jan-01
	 	Definitions – with Alternate paragraph (h) (Jan 2001)
	HHSAR

	 	352.216-72
	 	Oct-90
	 	Additional Cost Principles
	HHSAR

	 	352.228-7
	 	Dec-91
	 	Insurance – Liability to Third Persons
	HHSAR

	 	352.232-9
	 	Apr-84
	 	Withholding of Contract Payments
	HHSAR

	 	352.233-70
	 	Apr-84
	 	Litigation and Claims
	HHSAR

	 	352.242-71
	 	Apr-84
	 	Final Decisions on Audit Findings
	HHSAR

	 	352.270-5
	 	Apr-84
	 	Key Personnel
	HHSAR

	 	352.270-6
	 	Jul-91
	 	Publications and Publicity
	HHSAR

	 	352.270-7
	 	Jan-01
	 	Paperwork Reduction Act






 





*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



 









 





EXHIBIT
B — Statement of Work




***




 





*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.



 









 





EXHIBIT
C — Summary of Proposed Costs




***




 





*** Information redacted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.